{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:11:29Z","timestamp":1790377889383,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s43032-025-01788-9","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T13:15:57Z","timestamp":1738156557000},"page":"1661-1675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis"],"prefix":"10.1007","volume":"32","author":[{"given":"Yuzi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1988-3952","authenticated-orcid":false,"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"1788_CR1","doi-asserted-by":"crossref","unstructured":"Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med 2023, 12(4).","DOI":"10.3390\/jcm12041454"},{"issue":"5","key":"1788_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467\u2013520.","journal-title":"Endocr Rev"},{"key":"1788_CR3","doi-asserted-by":"publisher","first-page":"117955811987404","DOI":"10.1177\/1179558119874042","volume":"13","author":"TM Barber","year":"2019","unstructured":"Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042.","journal-title":"Clin Med Insights Reprod Health"},{"key":"1788_CR4","doi-asserted-by":"publisher","first-page":"1294406","DOI":"10.3389\/fendo.2023.1294406","volume":"14","author":"S Malik","year":"2023","unstructured":"Malik S, Saeed S, Saleem A, Khan MI, Khan A, Akhtar MF. Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs. Front Endocrinol (Lausanne). 2023;14:1294406.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1788_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11892-024-01539-1","volume":"24","author":"S Chaudhary","year":"2024","unstructured":"Chaudhary S, Kulkarni A. Metformin: past, Present, and Future. Curr Diab Rep. 2024;24(6):119\u201330.","journal-title":"Curr Diab Rep"},{"issue":"2","key":"1788_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","volume":"8","author":"A Yerevanian","year":"2019","unstructured":"Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019;8(2):156\u201364.","journal-title":"Curr Obes Rep"},{"key":"1788_CR7","doi-asserted-by":"publisher","first-page":"204201882092600","DOI":"10.1177\/2042018820926000","volume":"11","author":"R Pu","year":"2020","unstructured":"Pu R, Shi D, Gan T, Ren X, Ba Y, Huo Y, Bai Y, Zheng T, Cheng N. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020;11:2042018820926000.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1788_CR8","doi-asserted-by":"crossref","unstructured":"Jensterle M, Herman R, Jane\u017e A. Therapeutic potential of glucagon-like Peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives. Biomedicines 2022, 10(8).","DOI":"10.3390\/biomedicines10081989"},{"key":"1788_CR9","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.","journal-title":"Mol Metab"},{"issue":"1","key":"1788_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12902-023-01497-x","volume":"23","author":"Y Hu","year":"2023","unstructured":"Hu Y, Song X, Hamiti S, Ma Y, Yusufu M, Wang X, Zhang K, Guo Y. Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. BMC Endocr Disorders. 2023;23(1):250.","journal-title":"BMC Endocr Disorders"},{"issue":"2","key":"1788_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40618-021-01666-6","volume":"45","author":"JJ Ge","year":"2022","unstructured":"Ge JJ, Wang DJ, Song W, Shen SM, Ge WH. The effectiveness and safety of liraglutide in treating overweight\/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest. 2022;45(2):261\u201373.","journal-title":"J Endocrinol Invest"},{"key":"1788_CR12","doi-asserted-by":"crossref","unstructured":"Popoviciu MS, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a Comprehensive Review of Randomised controlled trials. Int J Mol Sci 2023, 24(13).","DOI":"10.3390\/ijms241310449"},{"issue":"1","key":"1788_CR13","doi-asserted-by":"publisher","first-page":"2219342","DOI":"10.1080\/09513590.2023.2219342","volume":"39","author":"J Gan","year":"2023","unstructured":"Gan J, Chen J, Ma RL, Deng Y, Ding XS, Zhu SY, Sun AJ. Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone. Gynecol Endocrinol. 2023;39(1):2219342.","journal-title":"Gynecol Endocrinol"},{"issue":"7","key":"1788_CR14","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1788_CR15","doi-asserted-by":"publisher","first-page":"4288004","DOI":"10.1155\/2023\/4288004","volume":"2023","author":"J Gan","year":"2023","unstructured":"Gan J, Chen J, Ma RL, Deng Y, Ding XS, Zhu SY, Sun AJ. Action mechanisms of Metformin combined with Exenatide and Metformin only in the treatment of PCOS in obese patients. Int J Endocrinol. 2023;2023:4288004.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"1788_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"23","key":"1788_CR17","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1097\/CM9.0000000000001712","volume":"134","author":"RL Ma","year":"2021","unstructured":"Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome. Chin Med J (Engl). 2021;134(23):2882\u20139.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"1788_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1\u201311.","journal-title":"Eur J Endocrinol"},{"key":"1788_CR19","doi-asserted-by":"crossref","unstructured":"Wen Q, Fang S, Liang Y, Tian Y, Chen Y, Yuan J, Chen Q. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. Front Endocrinol 2023;14.","DOI":"10.3389\/fendo.2023.1156521"},{"key":"1788_CR20","doi-asserted-by":"crossref","unstructured":"Xing C, Zhao H, Zhang J, He B. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol 2022;13.","DOI":"10.3389\/fendo.2022.945609"},{"key":"1788_CR21","doi-asserted-by":"publisher","first-page":"1156521","DOI":"10.3389\/fendo.2023.1156521","volume":"14","author":"Q Wen","year":"2023","unstructured":"Wen Q, Fang S, Liang Y, Tian Y, Chen Y, Yuan J, Chen Q. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. Front Endocrinol (Lausanne). 2023;14:1156521.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"1788_CR22","doi-asserted-by":"publisher","first-page":"e045663","DOI":"10.1136\/bmjopen-2020-045663","volume":"11","author":"E Brown","year":"2021","unstructured":"Brown E, Wilton MM, Sprung VS, Harrold JA, Halford JCG, Stancak A, Burgess M, Howarth E, Umpleby AM, Kemp GJ, et al. A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. BMJ Open. 2021;11(7):e045663.","journal-title":"BMJ Open"},{"key":"1788_CR23","doi-asserted-by":"publisher","first-page":"155237","DOI":"10.1016\/j.metabol.2022.155237","volume":"133","author":"L Valenzuela-Vallejo","year":"2022","unstructured":"Valenzuela-Vallejo L, Chrysafi P, Bello-Ramos J, Bsata S, Mantzoros CS. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity. Metabolism. 2022;133:155237.","journal-title":"Metabolism"},{"issue":"11","key":"1788_CR24","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/dom.13824","volume":"21","author":"RE Pratley","year":"2019","unstructured":"Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Jacob S, Yoon KH. Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study. Diabetes Obes Metab. 2019;21(11):2429\u201339.","journal-title":"Diabetes Obes Metab"},{"key":"1788_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/B978-0-12-800101-1.00002-8","volume":"121","author":"P Nadkarni","year":"2014","unstructured":"Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23\u201365.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"1788_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/10790268.2016.1195071","volume":"41","author":"JS Liu","year":"2018","unstructured":"Liu JS, Dong C, Vo AX, Dickmeyer LJ, Leung CL, Huang RA, Kielb SJ, Mukherjee S. Obesity and anthropometry in spina bifida: what is the best measure. J Spinal Cord Med. 2018;41(1):55\u201362.","journal-title":"J Spinal Cord Med"},{"key":"1788_CR27","doi-asserted-by":"crossref","unstructured":"Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares M, de Souza GA, Fidalgo TM, Ara\u00fajo AC, de Souza Gonzaga HF, de Bortoli Teixeira D et al. de Oliveira Silva Ullmann T: GLP-1a: Going beyond Traditional Use. Int J Mol Sci 2022, 23(2).","DOI":"10.3390\/ijms23020739"},{"issue":"9","key":"1788_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/17512433.2021.1933433","volume":"14","author":"M Siamashvili","year":"2021","unstructured":"Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021;14(9):1081\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1788_CR29","doi-asserted-by":"publisher","first-page":"101163","DOI":"10.1016\/j.molmet.2021.101163","volume":"45","author":"R Hanssen","year":"2021","unstructured":"Hanssen R, Kretschmer AC, Rigoux L, Albus K, Edwin Thanarajah S, Sitnikow T, Melzer C, Cornely OA, Br\u00fcning JC, Tittgemeyer M. GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. Mol Metab. 2021;45:101163.","journal-title":"Mol Metab"},{"issue":"Pt","key":"1788_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2015.02.017","volume":"418","author":"D Sandoval","year":"2015","unstructured":"Sandoval D, Sisley SR. Brain GLP-1 and insulin sensitivity. Mol Cell Endocrinol. 2015;418(Pt):27\u201332.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"1788_CR31","doi-asserted-by":"publisher","first-page":"112529","DOI":"10.1016\/j.celrep.2023.112529","volume":"42","author":"W Xu","year":"2023","unstructured":"Xu W, Qadir MMF, Nasteska D, Mota de Sa P, Gorvin CM, Blandino-Rosano M, Evans CR, Ho T, Potapenko E, Veluthakal R, et al. Architecture of androgen receptor pathways amplifying glucagon-like peptide-1 insulinotropic action in male pancreatic \u03b2 cells. Cell Rep. 2023;42(5):112529.","journal-title":"Cell Rep"},{"issue":"6","key":"1788_CR32","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/humrep\/deab065","volume":"36","author":"E Bosch","year":"2021","unstructured":"Bosch E, Alviggi C, Lispi M, Conforti A, Hanyaloglu AC, Chuderland D, Simoni M, Raine-Fenning N, Cr\u00e9pieux P, Kol S, et al. Reduced FSH and LH action: implications for medically assisted reproduction. Hum Reprod. 2021;36(6):1469\u201380.","journal-title":"Hum Reprod"},{"key":"1788_CR33","doi-asserted-by":"crossref","unstructured":"Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res 2018, 2018:4020492.","DOI":"10.1155\/2018\/4020492"},{"key":"1788_CR34","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013 state-of-the-art. Mol Metabolism. 2021;46:101102.","journal-title":"Mol Metabolism"},{"key":"1788_CR35","doi-asserted-by":"publisher","first-page":"204201882199732","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic Adv Endocrinol Metabolism. 2021;12:2042018821997320.","journal-title":"Therapeutic Adv Endocrinol Metabolism"},{"issue":"S3","key":"1788_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.15749","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii GA. Optimizing metformin therapy in practice: tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes. Diabetes Obes Metabolism. 2024;26(S3):42\u201354.","journal-title":"Diabetes Obes Metabolism"},{"issue":"3","key":"1788_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426\u201335.","journal-title":"Diabetologia"},{"issue":"2","key":"1788_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","volume":"65","author":"R DeFronzo","year":"2016","unstructured":"DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20\u20139.","journal-title":"Metabolism"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-01788-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-025-01788-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-01788-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:29:12Z","timestamp":1745926152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-025-01788-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s43032-025-01788-9","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate are not necessary since this study was a meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}